According to a new Netscribes report published by Research on Global Markets, the global non-alcoholic steatohepatitis (NASH) diagnostics market is expected to witness a significant compound annual growth rate (CAGR) during the forecasted period of 2018-2023.

According to the report, increasing incidence of type 2 diabetes across the world and rising obesity levels of the global population are leading to the growing prevalence of non-alcoholic steatohepatitis (NASH), especially in developed nations. These factors will drive the growth of the NASH diagnostics market over the forecasted period. The findings of the report suggest that NASH affects around 12% of the world’s adult population. More than 80% of NASH patients are obese, 44% have type 2 diabetes, and 72% have abnormal blood lipids (triglycerides and cholesterol).

Segment wise, liver biopsy is the most popular diagnostic technique for NASH detection and is usually preferred by medical practitioners, owing to its ability to determine the degree of steatosis and inflammation accurately. Based on regions, North America holds the largest share of the NASH diagnostics market. The growing prevalence of obesity and type 2 diabetes is leading to an increase in the number of patients suffering from NASH in this region, according to the Nestscribes’ report.

Key highlights of this report:

  • Scope and segmentation of the global NASH diagnostics market
  • Global market overview - historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), geography-wise market revenue (USD Mn), and market attractiveness analysis
  • Qualitative analysis of the drivers and challenges affecting the market and its segments
  • Analysis of the competitive landscape and profiles of the major players operating in the market
  • Detailed analysis of the key developments and major innovations in the market
  • Market segmentation based on diagnostic technique - (imaging [magnetic resonance imaging {MRI}, ultrasonography, and computed tomography {CT}], liver biopsy, and biomarkers [serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others]) - historical (2015-2017) and forecasted (2018-2023) market size (USD Mn), and key market observations

This report has been formulated and designed with the purpose of giving businesses a concise understanding of the demand for NASH diagnostic techniques across the world to determine the viability of the market, aiding them to develop strategies based on the drivers, and helping brands to identify competition and respond accordingly.

Name: Ankita Basu
US Toll-Free: 18888313350
M: +91 9903154956